VRCAVerrica Pharmaceuticals Inc.

Nasdaq verrica.com


$ 9.54 $ 1.56 (19.5 %)    

Monday, 13-May-2024 15:58:59 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 9.56
$ 8.10
$ 9.53 x 200
$ 9.58 x 100
$ 8.10 - $ 9.56
$ 2.86 - $ 9.61
562,124
na
444.38M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-17-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-13-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 verrica-pharmaceuticals-lead-product-ycanth-has-received-new-chemical-entity-status-and-a-listing-in-the-orange-book-from-the-fda-providing-a-minimum-of-five-years-of-regulatory-exclusivity

NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent appl...

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 hc-wainwright--co-maintains-buy-on-verrica-pharmaceuticals-raises-price-target-to-13

HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price ...

 verrica-pharmaceuticals-q4-eps-053-inline-sales-199m-beat-91000k-estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. ...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 top-4-health-care-stocks-that-may-crash-this-month

As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

 insiders-buying-pfizer-and-3-other-stocks

Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.

 jefferies-reiterates-buy-on-verrica-pharmaceuticals-maintains-10-price-target

Jefferies analyst Glen Santangelo reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $10 price target.

 why-quanex-building-products-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION